The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I find it odd that Stuart would communicate to investors through Belgrano.
Amers…. Agree. If MRK can pull the strings to get EUA, they will have a head start against SNG.
Yes and with the price point of $700, if it gets EUA, it will eat our lunch before we even sit down.
A local woman (Surrey) who was in hospital for covid posted a comment on a local community forum thanking her doctors and warning people of the dangers of covid. There have been many similar messages by others but what caught my attention was her mention of nebulisers during treatment. Would be proud if sng played a role in her recovery.
Does anyone know the compensation received by senior mgt? This is a good initial indication of whether the mgt is fiscally responsible or using the firm to stuff their pockets. I will hold if the former but if they are just running down the clock until there is no more money, then best to leave sooner than later.
Shares of small covid-related biotech companies were going nuts over the past few days fueled by the acquisition of Translate Bio by Sanofi. I suspect some of that excitement spilled over to SNG.
Hindsight is 20/20 but having invested in SNG and BNTX and watching the latter pop 22% before coming down to +17%, I have to wonder whether SNG management dropped the ball in going about this alone without a big pharma partner.
https://www.wsj.com/articles/covid-treatment-delta-variant-cases-symptoms-11627312440?mod=hp_lead_pos5
Good reminder of why it is taking so long :
1. approx 225 trials
2. government focus on vaccines rather than treatments
3. not enough publicity re treatments to educate doctors and patients of trials
I have similar amount riding on SNG. I have also been investing in other covid stocks (Moderna and Biontech). In all 3, I had followed the trials and read the reports in detail with medical professionals (family members). The trials for the covid vaccs left little risk on the downside and I expect it will be the same with SNG (famous last words? lol).
GLA
Thanks again, MilkyTea. I know the trial wasn't designed in the same way as, say the Biontech/Pfizer vaccine trial. Was just curious at how different in order to assess the potential for negative surprises. But given the high success rate of nearly 75%, I think a significant amount of room for error can be afforded and the supplement would still be attractive to consumers.
Thanks Milkytea. I see. Did you have to send photos of your condition as part of the application and how did they confirm your condition? The bar was set lower for this trial compared to a usual medical trial, e.g. the covid vaccine trials where they gave placebos to some of the participants as a control group. I am just curious how low a bar was set.
Hi MilkyTea, thanks for your feedback. This gave me further encouragement to buy more shares yesterday. Mind if I ask you a question? I was discussing this with my wife who has a medical background on the trial and she wondered how applicants were screened and do you know if the trial was run by a 3rd party? Thanks!
Funny - all of this talk of buyout does remind me of when the start-up I worked for at the time was acquired back in 2010. It had very good growth prospects but lacked the capital and size to make it a world beater. It was also beaten down by the financial crisis. The share price was limping along and then boom, it was up 50%. The key thing is not losing sight of the value of the product. If it works, someone who eventually pay you its fair market value.
Ah sorry Fruit. I didn't see your follow up comment clarifying your initial comment.
The founder of Citadel is Ken Griffin not Reade Griffith.
Is this considered a lot?
"Expanding the collaboration with the University was one of the areas of investment laid out by the Company when it raised funds via placing and open offer in October 2020." - I initially thought that this could have waited until after the trial when hopefully the share price pops but the more I think about it, the more I think it is a prudent risk averse move that secures funding for research regardless of the trial outcomes. Any other thoughts on whether this was a good dilution?
I don't day trade so don't keep an eye on the order flows but numerous 25K share buys is encouraging, particularly for a micro-cap stock. Thanks for sharing.
I see. Insider buying?
That's like £6000. Nothing to get excited over surely.